Bemcentinib - BerGenBio

Drug Profile

Bemcentinib - BerGenBio

Alternative Names: BGB 324; R-428

Latest Information Update: 13 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Rigel Pharmaceuticals
  • Developer BerGenBio; Haukeland University Hospital; Merck Sharp & Dohme; University of Texas Southwestern Medical Center
  • Class Antineoplastics; Benzocycloheptenes; Cycloheptanes; Pyridazines; Pyrrolidines; Small molecules; Triazoles
  • Mechanism of Action Axl receptor tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Malignant melanoma; Non-small cell lung cancer
  • Phase I/II Myelodysplastic syndromes
  • Phase I Acute myeloid leukaemia
  • Preclinical Idiopathic pulmonary fibrosis; Non-alcoholic steatohepatitis
  • No development reported Chronic myeloid leukaemia; Pancreatic cancer; Solid tumours

Most Recent Events

  • 05 Sep 2018 University of Leicester plans the phase II MiST trial for Mesothelioma (Second-line therapy or greater, Combination therapy) in United Kingdom in October 2018 (NCT03654833)
  • 28 Aug 2018 BerGenBio plans a phase I/II trial for Pancreatic cancer (Combination therapy, Metastatic disease, Recurrent, Second-line or greater) in November 2018 (NCT03649321)
  • 14 Jun 2018 Pharmacodynamics data from the phase Ib/II BGBC003 trial in Acute myeloid leukaemia presented at the 23rd Congress of the European Haematology Association (EHA - 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top